Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > 8:38 Level 2

<< Previous

Bullboard Posts

Next >>

Post by cra1gBon Mar 01, 2021 8:38am

183 Views

Post# 32683923

8:38 Level 2

$0.09	2189000	65	$0.09	2678000	67
$0.08	48000	4	$0.095	891000	12
$0.075	273000	11	$0.10	2046000	28
$0.07	1061000	37	$0.105	91000	4
$0.065	439000	27	$0.11	840000	12
$0.06	739000	26	$0.115	1000	1
$0.055	561000	17	$0.12	1277000	12
$0.05	1436000	21	$0.125	5000	2
$0.045	932000	13	$0.13	245000	7
$0.04	1742000	25	$0.135	545000	3